Biocept
Plus Therapeutics, Biocept Ink Lab Services Agreement for ReSPECT-LM Trial
Biocept will test patients with its CNSide cerebrospinal fluid cell capture assay to evaluate responses to Plus' radiotherapy drug candidate.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Quest Diagnostics to Offer Biocept's Target Selector NGS Lung Cancer Test
The liquid biopsy test is intended for identifying genetic mutations to guide therapy in patients with advanced non-small cell lung cancer.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept, Protean BioDiagnostics Team up to Study EGFR Assay in Lung Cancer
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.